Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up.
Hengstman
G J D
GJ
Neuromuscular Center Nijmegen, Institute of Neurology, University Medical Center Nijmegen, PO Box 9101, NL-6500 HB Nijmegen, The Netherlands. g.hengstman@neuro.umcn.nl
van den Hoogen
F H J
FH
van Engelen
B G M
BG
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood; D003882:Dermatomyositis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D017285:Polymyositis / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D000906:Antibodies; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D003402:Creatine Kinase; D011241:Prednisone; D008727:Methotrexate